| Literature DB >> 30680584 |
Yi Luo1,2, Anqi Zeng3, Aiping Fang2, Linjiang Song4, Chen Fan2, Chenjuan Zeng2, Tinghong Ye2, Hao Chen5, Chongqi Tu1, Yongmei Xie6.
Abstract
Osteosarcoma is the most common primary malignancy of bone and characterized by an appendicular primary tumor with a high rate of metastasis to the lungs. Unfortunately, there is no effective strategy to treat osteosarcoma in current clinical practice. In this study, the anticancer effects and potential mechanisms of nifuroxazide, an oral nitrofuran antibiotic, on two osteosarcoma cell lines were investigated. The results of the antiproliferative activity in vitro showed that nifuroxazide inhibited cell proliferation of UMR106 and MG63 cells in a dose- and time-dependent manner. Interestingly, nifuroxazide showed low toxicity to non-tumor cells (HEK 293 T). In addition, ROS-mitochondrial mediated apoptosis was observed after treatment of nifuroxazide. Moreover, nifuroxazide could significantly inhibit osteosarcoma cells migration and invasion via p-Stat3, MMP-2 and MMP-9 mediated signaling pathway. Taken together, our results suggested that nifuroxazide could be a promising agent for osteosarcoma treatment by inhibiting cell proliferation, inducing cell apoptosis and impairing cell migration and invasion.Entities:
Keywords: Anti-metastasis; Anti-proliferation; Apoptosis; Nifuroxazide; Osteosarcoma
Year: 2019 PMID: 30680584 DOI: 10.1007/s10637-019-00724-4
Source DB: PubMed Journal: Invest New Drugs ISSN: 0167-6997 Impact factor: 3.850